Acute mania: Haloperidol dose and augmentation with lithium or lorazepam

James C Y Chou, P. Czobor, Owen Charles, Ivan Tuma, Bertrand Winsberg, Michael H. Allen, Manuel Trujillo, Jan Volavka

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Antipsychotic dosing for acute mania has not been well studied. Combined treatment with lithium and an antipsychotic is the most common treatment, but additional antimanic efficacy of a lithium-antipsychotic combination beyond that of an antipsychotic alone has not been well demonstrated. Furthermore, the possibility that lithium could affect antipsychotic dose requirement is believed to have never been studied. In this study, 63 acutely psychotic bipolar manic inpatients were randomly assigned to receive double-blind treatment with 1 of 2 haloperidol doses, 25 mg/day or 5 mg/day, for 21 days. In addition to haloperidol, subjects were randomly assigned to receive concomitant treatment with placebo, standard lithium, or lorazepam 4 mg/day. The high haloperidol dose produced greater improvement and more side effects than did the low dose. Lithium added to the low dose produced a markedly greater clinical response than did the low dose alone. Lorazepam did not improve the outcome for the patients receiving low-dose haloperidol. The clinical response produced by high-dose haloperidol was not enhanced by adding either lithium or lorazepam. All treatment effects emerged by the fourth day of treatment and persisted. Used alone, a haloperidol dose of 5 mg/day is too low for most manic patients, but concomitant lithium produces a dose-dependent enhancement of haloperidol response. Lorazepam 4 mg/day was insufficient to produce an advantage when added to low-dose haloperidol.

Original languageEnglish
Pages (from-to)500-505
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 1999

Fingerprint

Lorazepam
Haloperidol
Bipolar Disorder
Lithium
Antipsychotic Agents
Therapeutics
Antimanic Agents
Inpatients
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Acute mania : Haloperidol dose and augmentation with lithium or lorazepam. / Chou, James C Y; Czobor, P.; Charles, Owen; Tuma, Ivan; Winsberg, Bertrand; Allen, Michael H.; Trujillo, Manuel; Volavka, Jan.

In: Journal of Clinical Psychopharmacology, Vol. 19, No. 6, 12.1999, p. 500-505.

Research output: Contribution to journalArticle

Chou, JCY, Czobor, P, Charles, O, Tuma, I, Winsberg, B, Allen, MH, Trujillo, M & Volavka, J 1999, 'Acute mania: Haloperidol dose and augmentation with lithium or lorazepam', Journal of Clinical Psychopharmacology, vol. 19, no. 6, pp. 500-505. https://doi.org/10.1097/00004714-199912000-00003
Chou, James C Y ; Czobor, P. ; Charles, Owen ; Tuma, Ivan ; Winsberg, Bertrand ; Allen, Michael H. ; Trujillo, Manuel ; Volavka, Jan. / Acute mania : Haloperidol dose and augmentation with lithium or lorazepam. In: Journal of Clinical Psychopharmacology. 1999 ; Vol. 19, No. 6. pp. 500-505.
@article{f7d987366f244be09d49c062e1e917ad,
title = "Acute mania: Haloperidol dose and augmentation with lithium or lorazepam",
abstract = "Antipsychotic dosing for acute mania has not been well studied. Combined treatment with lithium and an antipsychotic is the most common treatment, but additional antimanic efficacy of a lithium-antipsychotic combination beyond that of an antipsychotic alone has not been well demonstrated. Furthermore, the possibility that lithium could affect antipsychotic dose requirement is believed to have never been studied. In this study, 63 acutely psychotic bipolar manic inpatients were randomly assigned to receive double-blind treatment with 1 of 2 haloperidol doses, 25 mg/day or 5 mg/day, for 21 days. In addition to haloperidol, subjects were randomly assigned to receive concomitant treatment with placebo, standard lithium, or lorazepam 4 mg/day. The high haloperidol dose produced greater improvement and more side effects than did the low dose. Lithium added to the low dose produced a markedly greater clinical response than did the low dose alone. Lorazepam did not improve the outcome for the patients receiving low-dose haloperidol. The clinical response produced by high-dose haloperidol was not enhanced by adding either lithium or lorazepam. All treatment effects emerged by the fourth day of treatment and persisted. Used alone, a haloperidol dose of 5 mg/day is too low for most manic patients, but concomitant lithium produces a dose-dependent enhancement of haloperidol response. Lorazepam 4 mg/day was insufficient to produce an advantage when added to low-dose haloperidol.",
author = "Chou, {James C Y} and P. Czobor and Owen Charles and Ivan Tuma and Bertrand Winsberg and Allen, {Michael H.} and Manuel Trujillo and Jan Volavka",
year = "1999",
month = "12",
doi = "10.1097/00004714-199912000-00003",
language = "English",
volume = "19",
pages = "500--505",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Acute mania

T2 - Haloperidol dose and augmentation with lithium or lorazepam

AU - Chou, James C Y

AU - Czobor, P.

AU - Charles, Owen

AU - Tuma, Ivan

AU - Winsberg, Bertrand

AU - Allen, Michael H.

AU - Trujillo, Manuel

AU - Volavka, Jan

PY - 1999/12

Y1 - 1999/12

N2 - Antipsychotic dosing for acute mania has not been well studied. Combined treatment with lithium and an antipsychotic is the most common treatment, but additional antimanic efficacy of a lithium-antipsychotic combination beyond that of an antipsychotic alone has not been well demonstrated. Furthermore, the possibility that lithium could affect antipsychotic dose requirement is believed to have never been studied. In this study, 63 acutely psychotic bipolar manic inpatients were randomly assigned to receive double-blind treatment with 1 of 2 haloperidol doses, 25 mg/day or 5 mg/day, for 21 days. In addition to haloperidol, subjects were randomly assigned to receive concomitant treatment with placebo, standard lithium, or lorazepam 4 mg/day. The high haloperidol dose produced greater improvement and more side effects than did the low dose. Lithium added to the low dose produced a markedly greater clinical response than did the low dose alone. Lorazepam did not improve the outcome for the patients receiving low-dose haloperidol. The clinical response produced by high-dose haloperidol was not enhanced by adding either lithium or lorazepam. All treatment effects emerged by the fourth day of treatment and persisted. Used alone, a haloperidol dose of 5 mg/day is too low for most manic patients, but concomitant lithium produces a dose-dependent enhancement of haloperidol response. Lorazepam 4 mg/day was insufficient to produce an advantage when added to low-dose haloperidol.

AB - Antipsychotic dosing for acute mania has not been well studied. Combined treatment with lithium and an antipsychotic is the most common treatment, but additional antimanic efficacy of a lithium-antipsychotic combination beyond that of an antipsychotic alone has not been well demonstrated. Furthermore, the possibility that lithium could affect antipsychotic dose requirement is believed to have never been studied. In this study, 63 acutely psychotic bipolar manic inpatients were randomly assigned to receive double-blind treatment with 1 of 2 haloperidol doses, 25 mg/day or 5 mg/day, for 21 days. In addition to haloperidol, subjects were randomly assigned to receive concomitant treatment with placebo, standard lithium, or lorazepam 4 mg/day. The high haloperidol dose produced greater improvement and more side effects than did the low dose. Lithium added to the low dose produced a markedly greater clinical response than did the low dose alone. Lorazepam did not improve the outcome for the patients receiving low-dose haloperidol. The clinical response produced by high-dose haloperidol was not enhanced by adding either lithium or lorazepam. All treatment effects emerged by the fourth day of treatment and persisted. Used alone, a haloperidol dose of 5 mg/day is too low for most manic patients, but concomitant lithium produces a dose-dependent enhancement of haloperidol response. Lorazepam 4 mg/day was insufficient to produce an advantage when added to low-dose haloperidol.

UR - http://www.scopus.com/inward/record.url?scp=0032750889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032750889&partnerID=8YFLogxK

U2 - 10.1097/00004714-199912000-00003

DO - 10.1097/00004714-199912000-00003

M3 - Article

C2 - 10587284

AN - SCOPUS:0032750889

VL - 19

SP - 500

EP - 505

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -